Last reviewed · How we verify
Essential hypertension
Approved treatments
- Cetapril · Par Pharm
- Verapamil Hydrochloride · Pfizer Inc.
Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells. - Moxonidin · University of Aarhus
- Selecal
Selecal works by blocking beta-1 adrenergic receptors in the heart, reducing heart rate and blood pressure. - Moxonidin
- Detantol
Detanidol works by blocking the alpha-1A adrenergic receptor, which helps to relax blood vessels and lower blood pressure.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Essential hypertension patent landscape — cliff calendar, originator estates, attackable patents
- Essential hypertension treatment landscape brief
- Essential hypertension treatment updates RSS
Frequently asked questions about Essential hypertension
What drugs treat Essential hypertension?
Tracked treatments include Cetapril, Verapamil Hydrochloride, Moxonidin, Selecal, Detantol.
What is the treatment for Essential hypertension?
Standard treatment for Essential hypertension includes Cetapril, Verapamil Hydrochloride, Moxonidin, Selecal, Detantol. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Essential hypertension patent cliff · Essential hypertension CI report
- Treatment: Cetapril · Par Pharm
- Treatment: Verapamil Hydrochloride · Pfizer Inc.
- Treatment: Moxonidin · University of Aarhus
- Treatment: Selecal
- Treatment: Moxonidin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing